SPTB and metabolic dysfunction-associated steatotic liver disease: Similarly, the rates of both sPTB and iPTB were significantly increased from 3.54% and 4.28% in all subjects to 5.47% (p = 6.18 × 10−6) and 8.49% (p = 3.0 × 10−16) in NAFLD subjects and 6.14% (p = 0.0018) and 17.03% (p < 10−31) in ICP subjects, respectively (Supplementary Fig. 3a, b and Supplementary Table 3).